Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

OBESITY

GLP1 receptor agonist overcomes SGLT2 inhibitor-related overeating

Sodium–glucose cotransporter 2 (SGLT2) inhibitor treatment affects central regulation of appetite and satiety, which results in increased carbohydrate intake. It has now been demonstrated that these effects might be blunted by combining SGLT2 inhibitors with glucagon-like peptide 1 receptor agonists to further facilitate weight loss in patients with type 2 diabetes mellitus.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

References

  1. Müller, T. D., Blüher, M., Tschöp, M. H. & DiMarchi, R. D. Nat. Rev. Drug Discov. 21, 201–223 (2022).

  2. Blüher, M. Nat. Rev. Endocrinol. 15, 288–298 (2019).

  3. Saper, C. B., Chou, T. C. & Elmquist, J. K. Neuron 36, 199–211 (2002).

  4. Stice, E., Spoor, S., Bohon, C., Veldhuizen, M. G. & Small, D. M. J. Abnorm. Psychol. 117, 924–935 (2008).

  5. Brown, E., Heerspink, H. J. L., Cuthbertson, D. J. & Wilding, J. P. H. Lancet 398, 262–276 (2021).

  6. Horie, I. et al. Diabetes Res. Clin. Pract. 135, 178–184 (2018).

  7. van Ruiten, C. C. et al. J. Clin. Endocrinol. Metab. 107, e2590–e2599 (2022).

  8. van Ruiten, C. C. et al. Diabetes Obes. Metab. https://doi.org/10.1111/dom.14732 (2022).

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Matthias Blüher.

Ethics declarations

Competing interests

M.B. received honoraria as a consultant and speaker from Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Lilly, Novo Nordisk, Novartis, Pfizer and Sanofi.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Blüher, M. GLP1 receptor agonist overcomes SGLT2 inhibitor-related overeating. Nat Rev Endocrinol 18, 523–524 (2022). https://doi.org/10.1038/s41574-022-00722-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41574-022-00722-2

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing